The clinical data (especially the resection) met and exceeded the requirements of the trial. I do not understand how they can now change their minds or the goalposts. These are sick patients. To be able to undergo surgery when it was initially inoperable is very beneficial.
This committee are unbelievable.
OSL is going to challenge their findings.
Ann: CE Marking Update, page-12
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $69.42K | 8.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 28673846 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 7597003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
